J Med Microbiol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thyagarajan, S. P.
Right arrow Articles by Madanagopalan, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thyagarajan, S. P.
Right arrow Articles by Madanagopalan, N.
Agricola
Right arrow Articles by Thyagarajan, S. P.
Right arrow Articles by Madanagopalan, N.

The Journal of Medical Microbiology, Vol 16, Issue 2 227-231, Copyright © 1983 by Society for General Microbiology

JOURNAL ARTICLE

Duration of hepatitis B surface antigenaemia and its correlation with the histopathological and clinical outcome in acute and chronic hepatitis

S. P. Thyagarajan, M. Panchanadam, S. Subramanian, T. Sundaravelu, K. B. Ahmed and N. Madanagopalan

The persistence of Hepatitis B surface antigen (HBsAg) in 156 patients with histopathologically proven acute viral hepatitis and 27 patients with chronic active hepatitis was assessed and correlated with their clinical and histopathological outcome; 1387 sequential serum samples were tested for HBsAg and its antibody (anti HBs). In the group with acute viral hepatitis, 86% of the patients who recovered, 67% of the patients who deteriorated histopathologically and 67% of the fatal cases carried HBsAg for up to 8 weeks only. While 56% of patients with chronic active hepatitis harboured HBsAg for 13-80 weeks, only 10% of the group with acute viral hepatitis did so. Of patients with chronic active hepatitis 37% deteriorated to cirrhosis and 11% died. Diverse anti-HBs-response patterns are reported and may have clinical significance.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
F. Kanwal, I. M. Gralnek, P. Martin, G. S. Dulai, M. Farid, and B. M.R. Spiegel
Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis
Ann Intern Med, May 17, 2005; 142(10): 821 - 831.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 1983 Society for General Microbiology.